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Objectives. We investigated the plasma levels of molecular 
markers for platelet activity and the thrombotic and fibrinolytic 
status in patients with hypertrophic cardiomyopathy and dilated 
cardiomyopathy to determine the activating site of coagulation in 
these disorders. 
Background. A thromboembolic event is a serious complication 
in patients with idiopathic cardiomyopathy. However, the activat- 
ing site of the coagulation system in idiopathic cardiomyopathy 
has not been fully investigated. 
Methods. We determined the plasma levels of molecular 
markers for platelet activity (platelet factor 4 and beta- 
thromboglobulin), thrombotic status (fibrinopeptide A and 
thrombin-antithrombin III complex) and fibrinolytic status (D- 
dimer and plasmin-alpha2-plasmin inhibitor complex) in 13 
patients with hypertrophic cardiomyopathy, 17 patients with 
dilated cardiomyopathy and 20 normal subjects. 
Results. Plasma levels of platelet factor 4, beta-thromboglobulin 
and plasmin-alpha2-plasmin inhibitor complex did not differ signif- 
icantly among the three groups, whereas plasma levels of fibrinopep- 
tide A and thrombin-antithrombin HI complex in both patient 
groups were significantly higher than those in normal subjects. 
Plasma levels of D-dimer in patients with dilated cardiomyopathy 
were significantly higher than those in patients with hypertrophic 
cardiomyopathy and normal groups. In patients with hypertrophic 
cardiomyopathy, both fibrinopeptide A and thrombin-antithrombin 
HI complex levels were significantly correlated with left atrial diam- 
eter. In patients with dilated cardiomyopathy, fibrinopeptide A and 
thrombin-antithrombin HI complex levels showed a positive correla- 
tion with left ventricular end-diastolic volume and a negative corre- 
lation with fractional shortening of the left ventricle. 
Conclusions. The activated coagulation system in patients with 
hypertrophic and dilated cardiomyopathy may be triggered by left 
atrial dilation in hypertrophic eardiomyopathy and left ventricu- 
lar enlargement and dysfunction in dilated cardiomyopathy. 
(J Am CoU Cardio11995;25:1634-40) 
A thromboembolic event is a serious complication in patients 
with idiopathic ardiomyopathy (1-7). The incidence of stroke 
is reported to be 3% per patient-year in hypertrophic obstruc- 
tive cardiomyopathy (2). Systemic or pulmonary embolism is 
more common in patients with hypertrophic cardiomyopathy 
and atrial fibrillation (1,2). At least 11% of patients with 
dilated cardiomyopathy ave one or more embolic event 
during the course of their illness (6), and mural thrombus i
more frequently observed in the left ventricle than in the left 
atrium (8). 
New molecular markers with higher sensitivity for assessing 
platelet activity and evaluating thrombotic and fibrinolytic 
status have made it possible to evaluate such activities in 
patients with valvular heart disease, ischemic heart disease, 
deep vein thrombosis, pulmonary embolism and cardiomyop- 
athy (9-15). Measurement of these markers may be used to 
identify patients at risk for thromboembolism. It was recently 
reported that the plasma levels of fibrinopeptide A and 
thrombin-antithrombin III complex are significantly increased 
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in patients with idiopathic cardiomyopathy, demonstrating a 
state of increased coagulability in this disorder (14,15). How- 
ever, there are no published studies revealing the activating 
sites of coagulation i  patients with idiopathic cardiomyopathy. 
We therefore investigated the plasma levels of molecular 
markers for platelet activity and the thrombotic and fibrinolytic 
status in patients with hypertrophic cardiomyopathy and di- 
lated cardiomyopathy to determine the activating site of 
coagulation i these disorders. 
Methods  
Characteristics of subjects. Hemostatic molecular markers 
were measured in 13 patients with hypertrophic cardiomyop- 
athy (7 men and 6 women, mean age 49 _+ 4 years) and in 17 
patients with dilated cardiomyopathy (9 men and 8 women, 
mean age 53 + 3 years). Their clinical characteristics are 
summarized in Table 1. Eight of the 13 patients with hyper- 
trophic cardiomyopathy were in New York Heart Association 
functional class I, 4 in class II and 1 in class IV. In the group 
with dilated cardiomyopathy, 1 patient was in New York Heart 
Association functional class I, 10 were in class II, 5 in class III 
and 1 was in class IV. All patients had normal sinus rhythm and 
no history of systemic emboli; they were receiving no hemor- 
rheologically active agents. The diagnosis of hypertrophic 
cardiomyopathy was based on clinical, echocardiographic and 
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Table 1. Clinical Characteristics of Patients With 
Idiopathic Cardiomyopathy 
HCM DCM 
(n = 13) (n = 17) 
Male/female 7/6 
Mean age (yr) 49 _+ 
NYHA class 
I 8 
II 4 
III 0 
IV 1 
Left atrial diameter (mm) 46 -+ 
Left ventricular end-diastolic diameter (mm) 46 _+ 
Left ventricular end-diastolic volume (ml) 133 -+ 
Fractional shortening (%) 40 -+ 
Mitral regurgitaton (moderate or severe) 10 
9/8 
4 53_+3 
1 
10 
5 
1 
2 43 + 
2 65 -+ 
5 262 _+ 
3 17 _+ 
5 
2 
2 
11 
1 
Data are expressed as mean value _+ SEM or number of patients. DCM 
dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy; NYHA class 
New York Heart Association functional class. 
angiographic riteria, including a nondilated asymmetrically 
hypertrophied left ventricle and absence of other cardiac or 
systemi c diseases causing left ventricular hypertrophy (16,17). 
Dilated cardiomyopathy was defined as global eft ventricular 
dysfunction with fractional shortening of the left ventricle 
<26% and a left ventricular end-diastolic diameter >56 ram. 
Criteria for exclusion from the study included the presence of 
significant valvular heart disease (except for relative incompe- 
tence), arterial hypertension, acute myocarditis, significant 
coronary artery disease, intracardiac thrombus as detected by 
two-dimensional transthoracic and transesophageal chocardi- 
ography, smoking, diabetes mellitus and renal or hepatic 
insufficiency. The age-matched control group consisted of 20 
normal volunteers (12 men and 8 women, mean age 52 _+ 2 
years) who were receiving no medications. They were non- 
smokers with no evidence of metabolic, neoplastic or inflam- 
matory disease. All patients and volunteers signed informed 
consent forms before the study. 
M-mode, two-dimensional nd Doppler echocardiography 
were performed in all patients. Echocardiographic data are 
summarized in Table 1. Left atrial diameter and left ventricu- 
lar end-diastolic diameter were determined with the use of 
M-mode echocardiograms (18). Left ventricular end-diastolic 
volume was determined by the method of Teichholz et al. (19). 
Fractional shortening of the left ventricle was determined by 
using the M-mode echocardiogram in the standard manner: 
Fractional shortening = (EDD - ESD)/EDD, where EDD is 
end-diastolic diameter and ESD is end-systolic diameter. 
Blood sampling. Blood samples were obtained from pe- 
ripheral veins at 9 AM with precautions to minimize any 
potential for activation of clotting during sampling, using the 
two-syringe technique. Nine parts of whole blood were mixed 
with one part of 3.8% sodium citrate solution for assay of 
thrombin-antithrombin III complex and plasmin-alphaz- 
plasmin inhibitor complex. Four parts of whole blood were 
gently mixed with one part of a solution containing sodium 
Table 2. Molecular  Markers in Normal  Subjects and in Patients 
With Idiopathic Cardiomyopathy 
Normal 
Subjects HCM DCM 
(n = 20) (n = 13) (n : 17) 
PF4 (ng/ml) 14.95 _+ 1.56 t4.69 _+ 6.66 12.12 -+ 1.65 
Beta-TG (ng/ml) 34.55 +_ 3.78 35.00 + 6.63 43.41 +_ 5.02 
FPA (ng/ml) 1.22 +_ 0.17 6.72 _+ 1.11§ 7.27 + 0.93§ 
TAT (ng/ml) 1.71 _+ 0.15 3.04 _+ 0.39~ 3.29 +_ 0.465 
D-dimer (ng/ml) 65.80 -+ 6.40 54.31 + 7.17 109.3 __ 13.04"11 
PIC (/xg/ml) 0.71 _+ 0.05 0.66 -+ 0.11 0.81 ± 0.13 
*p < 0.01, tP < 0.002, :~p < 0.001, §p < 0.0001 versus normal subjects. 
lip < 0.01 versus patients with hypertrophic cardiomyopathy. Data are expressed 
as mean value + SEM. Beta-TG = beta-thromboglobulin; FPA = fibrinopeptide 
A; PF4 = platelet factor 4; PIC = plasmin-alpha2-plasmin inhibitor complex; 
TAT = thrombin-antithrombin III complex; other abbreviations as in Table 1. 
citrate, theophylline, adenosine and dipyridamole for assay of 
platelet factor 4 and beta-thromboglobulin (20). A volume of 
1.6 ml of whole blood was drawn into a plastic tube containing 
200 U heparin and 4,000 kiu (kallidinogenase inactivator unit) 
aprotinin for assay of fibrinopeptide A and D-dimer. All 
samples were placed on ice, and plasma was promptly sepa- 
rated by centrifugation at 2,000 g at 4°C for 30 rain, immedi- 
ately frozen and stored at -80°C until the molecular markers 
were assayed. Sampling was repeated within 1 month in five 
patients to confirm the consistency of plasma levels of these 
markers, and there was a significant correlation between the 
values obtained at first and second samplings (e.g., thrombin- 
antithrombin III complex, r = 0.93, p = 0.02; fibrinopeptide A, 
r = 0.98, p = 0.004). 
Plasma assays. Enzyme-linked immunosorbent assay 
kits (Diagnostica Stago, Asnieres, France) were used for 
the quantitative determination of platelet factor 4 and 
beta-thromboglobulin (20). Levels of fibrinopeptide & thrombin- 
antithrombin III complex, D-dimer and plasmin-alphaz-plasmha 
inhibitor complex were also determined with enzyme-linked 
immunosorbent assay kits (Diagnostica Stag6, Asnieres, France; 
Behringe Werke, Marburg, Germany; Agen Biomedical, Bris- 
bane, Australia, and Teijin, Tokyo, Japan, respectively) (21-24). 
Statistical analysis. Data were expressed as mean value _+ 
SEM. Statistical analyses were performed on a Macintosh 
Quadra 650 computer with use of the Stat View 4.0 application 
package. Differences were analyzed by the Kruskal-Wallis test, 
and subsequent pairwise comparisons were made by the Mann- 
Whitney U test. Simple linear regression analysis was used to 
compare measurements obtained by echocardiography and 
levels of molecular markers. A p value < 0.05 was considered 
statistically significant. 
Resu l ts  
Molecular marker levels in idiopathic cardiomyopathy. 
We first measured molecular marker levels in patients with 
hypertrophic cardiomyopathy and dilated cardiomyopathy and 
in normal subjects. Table 2 shows the plasma levels of platelet 
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Figure 1. Scatterplots showing plasma levels of fi- 
brinopeptide A (FPA) and thrombin-antithrombin 
III complex (TAT) in patients with hypertrophic 
cardiomyopathy (HCM) (n = 13), dilated cardiomy- 
opathy (DCM) (n = 17) and normal subjects (n = 
20). Plasma fibrinopeptide A and thrombin- 
antithrombin III complex levels were significantly 
higher in patients with hypertrophic cardiomyopa- 
thy and dilated cardiomyopathy than in normal 
subjects. Data are mean value _+ SEM. 
factor 4 and beta-thromboglobulin, reflecting platelet activity. 
Platelet factor 4 and beta-thromboglobulin levels did not differ 
significantly among the three groups. 
Plasma levels of fibrinopeptide A and thrombin-antithrombin 
iII complex, used as markers of fibrin generation and reflecting 
thrombotic status, appear in Figure 1 and Table 2. Plasma levels 
of fibrinopeptide A and thrombin-antithrombin III complex in 
the two patient groups significantly exceeded those in normal 
subjects. 
The plasma levels of D-dimer and plasmin-alpha2-plasmin 
inhibitor complex, which reflect active fibrinolysis, are shown 
in Figure 2 and Table 2. Plasma levels of D-dimer in patients 
with dilated cardiomyopathy significantly exceeded those in the 
normal subjects and in patients with hypertrophic cardiomy- 
opathy. However, plasma levels of plasmin-alphaz-plasmin 
inhibitor complex did not differ significantly among normal 
subjects and the two patient groups. 
Relation between molecular markers and echocardio- 
graphic findings. We investigated the relation between ele- 
vated coagulation activity and left atrial and left ventricular 
diameter. Plasma levels of fibrinopeptide A in patients with 
hypertrophic ardiomyopathy were significantly correlated 
with left atrial diameter (r = 0.70, p = 0.01) (Fig. 3). Plasma 
thrombin-antithrombin III complex levels also showed a posi- 
tive correlation with left atrial diameter (r = 0.65, p = 0.02). 
However, fibrinopeptide A and thrombin-antithrombin III 
complex levels were not significantly correlated with left ven- 
tricular end-diastolic volume in patients with hypertrophic 
cardiomyopathy (r = 0.45, p = 0.12 and r = 0.15, p = 0.64, 
respectively) (Fig. 4). 
In patients with dilated cardiomyopathy, plasma levels of 
fibrinopeptide A were significantly correlated with left ventric- 
ular end-diastolic volume (r = 0.58, p = 0.01) (Fig. 5). Plasma 
thrombin-antithrombin III complex levels also showed a posi- 
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Figure 2. Scatterplots showing plasma levels 
of D-dimer and plasmin-alpha2-plasmin in- 
hibitor complex (PIC) in patients with hyper- 
trophic cardiomyopathy (HCM) (n = 13), 
dilated cardiomyopathy (DCM) (n = 17) and 
normal subjects (n = 20). Plasma D-dimer 
levels in patients with dilated cardiomyopathy 
were significantly higher than those in pa- 
tients with hypertrophic cardiomyopathy and 
normal subjects. Plasma plasmin-alpha2- 
plasmin inhibitor complex levels were not 
significantly different among the three groups. 
Data are mean value _+ SEM. 
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Figure 3. Scatterplots showing a relation between fibrinopeptide A 
(FPA) and thrombin-antithrombin III complex (TAT) levels and left 
atrial diameter (LAD) in 13 patients with hypertrophic cardiomyopa- 
thy. Regression analysis revealed a significant relation between fibri- 
nopeptide A levels and left atrial diameter (y = 0.35x - 9.37, r = 0.70, 
p = 0.01) and between thrombin-antithrombin III complex levels and 
left atrial diameter (y = 0.12x - 2.44, r = 0.65, p = 0.02). 
tive correlation with left ventricular end-diastolic volume (r = 
0.53, p = 0.03). In contrast, fibrinopeptide A and thrombin- 
antithrombin III complex levels showed a negative correlation 
with fractional shortening (r = 0.72, p = 0.001 and r = 0.57, 
p = 0.02, respectively) (Fig. 6). However, fibrinopeptide A and 
thrombin-antithrombin III complex levels were not signifi- 
cantly correlated with left atrial diameter in patients with 
dilated cardiomyopathy (r = 0.35, p = 0.17 and r = 0.30, p = 
0.24, respectively) (Fig. 7). 
Discussion 
Our findings indicate that the coagulation system is acti- 
vated in patients with hypertrophic cardiomyopathy and di- 
lated cardiomyopathy, and that this event may be linked to left 
atrial dilation in patients with hypertrophic ardiomyopathy 
and to left ventricular enlargement and dysfunction i  patients 
with dilated cardiomyopathy. 
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Figure 4. Scatterplots showing a relation between fibrinopeptide A 
(FPA) and thrombin-antitbrombin III complex (TAT) levels and left 
ventricular end-diastolic volume (LVEDV) in 13 patients with hyper- 
trophic cardiomyopathy. Regression analysis revealed no significant 
relation between fibrinopeptide A levels and left ventricular end- 
diastolic volume (y = -0.10x + 20.43, r = 0.45, p = 0.12) or between 
thrombin-antithrombin III complex levels and left ventricular end- 
diastolic volume (y = -0.01x + 4.47, r = 0.15, p = 0.64). 
Thrombin specifically cleaves fibrinopeptide A (Acd-16) 
from the aminotermini of fibrinogen's alpha-chain and initiates 
fibrin generation (25). Thrombin is very rapidly bound and 
thereby inactivated by its main physiologic inhibitor, anti- 
thrombin III, producing thrombin-antithrombin III complex. 
Plasma fibrinopeptide A and thrombin-antithrombin III com- 
plex levels are highly sensitive markers for thrombin activity in 
vivo, because direct measurement of free thrombin is not 
possible owing to its very short half-life. Few studies (14,15) 
have evaluated the coagulation system of patients with idio- 
pathic cardiomyopathy using these hemostatic molecular 
markers. Asakura et al. (14) reported that the plasma levels of 
thrombin-antithrombin III complex and prothrombin fragment 
1+2 were moderately increased in patients with cardiomyop- 
athy and atrial fibrillation. In our study, the plasma levels of 
fibrhaopeptide A and thrombin-antithrombin III complex in 
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Figure 5. Scatterplots showing a relation between fibrinopeptide A 
(FPA) and thrombin-antithrombin III complex (TAT) levels and left 
ventricular end-diastolic volume (LVEDV) in 17 patients with dilated 
cardiomyopathy. Regression analysis revealed a positive relation be- 
tween fibrinopeptide A levels and left ventricular end-diastolic volume 
(y = 0.05x - 5.60, r = 0.58, p = 0.01) and between thrombin- 
antithrombin III complex levels and left ventricular end-diastolic 
volume (y = 0.02x - 2.53, r = 0.53, p = 0.03). 
patients with hypertrophic ardiomyopathy and dilated car- 
diomyopathy significantly exceeded those in normal subjects, a
finding that demonstrates a state of increased coagulability in 
those patients. In contrast, fibrinolytic marker plasmin-alphaz- 
plasmin inhibitor complex values were normal in all groups, 
whereas D-dimer values were elevated in patients with dilated 
cardiomyopathy. 
Atrial fibrillation develops in approximately 15% of pa- 
tients with hypertrophic cardiornyopathy (26,27). Because pa- 
tients with hypertrophic cardiomyopathy who also have atrial 
fibrillation have an increased risk of systemic embolism, the 
development of atrial fibrillation in these patients is believed to 
herald a poor prognosis (28,29). Hardarson et al. (1) noted 
systemic or pulmonary embolism in 11 of 119 patients with 
hypertrophic cardiomyopathy; 3 of the 11 patients had chronic 
atrial fibrillation and 1 had paroxysmal trial fibrillation. Henry 
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Figure 6. Scatterplots showing a relation between fibrinopeptide A 
(FPA) and thrombin-antithrombin III complex (TAT) levels and 
fractional shortening (FS) in 17 patients with dilated cardiomyopathy. 
Regression analysis revealed a negative relation between fibrinopep- 
tide A levels and fractional shortening (y = -0.54x + 16.60, r = 0.72, 
p = 0.001) and between thrombin-antithrombin III complex levels and 
fractional shortening (y = -0.21x + 6.94, r = 0.57, p = 0.02). 
et al. (30) reported that 9 of their 11 patients with asymmetric 
septal hypertrophy and emboli had a history of chronic or 
paroxysmal atrial fibrillation. Furlan et al. (2) reported an 
incidence of stroke in 5 of 150 patients with idiopathic 
hypertrophic subaortic stenosis and concluded that patients 
with atrial fibrillation had a high risk of stroke. Thus, it is 
assumed that the left atrium is the activating site of coagulation 
in patients with hypertrophic cardiomyopathy and atrial fibril- 
lation. In the present study, plasma levels of both fibrinopep- 
tide A and thrombin-antithrombin III complex in patients with 
hypertrophic ardiomyopathy showed a positive correlation 
with left atrial diameter, suggesting that the activation may 
occur within the enlarged left atrium. 
Left ventricular thrombus is frequently observed in patients 
with dilated cardiomyopathy using echocardiography. Falk et 
al. (31) reported that it was significantly more common in 
patients with dilated cardiomyopathy with fractional shorten- 
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Figure 7. Scatterplots showing a relation between fibrinopeptide A 
(FPA) and thrombin-antithrombin III complex (TAT) levels and left 
atrial diameter (LAD) in 17 patients with dilated cardiomyopathy. 
Regression analysis revealed no significant relation between fibrin- 
opeptide A levels and left atrial diameter (y = -0.18x + 14.71, r = 
0.35, p = 0.17) or between thrombin-antithrombin III complex levels 
and left atrial diameter (y = -0.07x + 6.47, r = 0.30, p = 0.24). 
ing _<10% than in those with fractional shortening of 11% to 
25%. Jung et al. (15) reported that mean urinary fibrinopep- 
tide A level in patients with dilated cardiomyopathy was not 
significantly greater in those with severe than in those with 
moderate left ventricular dilation, but the fractional area 
change was 0.18 _+ 0.08 and 0.26 + 0.10 in those with elevated 
and normal urinary fibrinopeptide A levels, respectively. These 
investigators assumed no correlation between the severity of 
left ventricular dilation and thrombin activation, but they 
noted a correlation between the severity of reduced systolic 
function and evidence of thrombin activation. In the present 
study, plasma levels of both fibrinopeptide A and thrombin- 
antithrombin III complex in patients with dilated cardio- 
myopathy showed a positive correlation with left ventricular 
end-diastolic volume, whereas fibrinopeptide A and thrombin- 
antithrombin III complex levels showed a negative correlation 
with fractional shortening. Therefore, we assume that both 
enlargement and dysfunction of the left ventricle may contrib- 
ute to the activated coagulation system of patients with dilated 
cardiomyopathy and that the activation may occur within the 
left ventricle. 
The controversy continues over the usefulness of anticoag- 
ulant agents in treating patients with idiopathic ardiomyopa- 
thy. Kyrle et al. (5) reported that arterial or pulmonary 
embolism occurred in 17 of 38 patients with dilated cardio- 
myopathy before initiation of oral anticoagulant therapy but 
that no episode of systemic embolism occurred during the 
period of oral anticoagulant therapy, thus demonstrating the 
usefulness of anticoagulant therapy in dilated cardiomyopathy. 
In a study of the clinical outcome of 52 consecutive patients 
with hypertrophic cardiomyopathy who developed paroxysmal 
or established atrial fibrillation, Robinson et al. (32) reported 
that amiodarone therapy was associated with a maintenance of 
sinus rhythm and fewer embolic episodes in those patients. 
However, no prior study indicated the usefulness of anticoag- 
ulant therapy in patients with hypertrophic cardiomyopathy. 
Limitations of the study. In this study, thrombin activation 
was correlated with increased atrial size in hypertrophic car- 
diomyopathy and with ventricular enlargement and dysfunc- 
tion in dilated cardiomyopathy, but the correlations were 
somewhat tenuous because the groups were small and each 
patient was studied only once. Furthermore, the scattergrams 
that failed to show any correlation between hemodynamic 
status or chamber dilation and coagulation markers may have 
been subject to beta errors. To definitely indicate where 
activation of coagulation occurs in these patients, local blood 
sampling at strategic points is required. 
Conclusions, In this study, we have revealed that patients 
with idiopathic ardiomyopathy exhibit hypercoagulability, and 
that the activating sites of coagulation are related to an 
enlarged left atrium in patients with hypertrophic cardiomyop- 
athy and an enlarged and dysfunctional left ventricle in pa- 
tients with dilated cardiomyopathy. However, it is obscure 
whether the patients with high levels of the coagulation 
markers are at greater isk of thromboembolism. Further 
studies are required to clarify the relation between the levels of 
the molecular markers and the actual development of throm- 
bus and to determine the indication for anticoagulant therapy 
in those patients. 
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